Anti-Human PCSK9 VHH Single Domain Antibody (TAB-0081CL-VHH) (CAT#: TAB-0081CL-VHH)

Figure 1 The effect of sdAbs on wild type (WT) PCSK9-induced LDLR degradation.

Naive HuH7 cells were incubated with 1 ug/mL of purified WT PCSK9 for 24 h in the absence (Control) or presence of 100 μg/mL of various sdAbs to PCSK9. The cells were then detached and analyzed by flow cytometry for cell surface LDLR.

Figure 2 The effect of sdAbs on WT PCSK9-induced LDLR degradation.

Naive HuH7 cells were incubated with 1 μg/mL of purified WT PCSK9 for 24 h in the absence (Control) or presence of 50 μg/mL of various sdAbs to PCSK9. The cells were then detached and analyzed by flow cytometry for cell surface LDLR.

Figure 3 The effect of sdAbs on WT PCSK9-induced LDLR degradation.

Flow cytometry of cell surface LDLR (level of LDLR Expression.

Figure 4 The effect of sdAbs on WT PCSK9-induced LDLR degradation.

Naive HuH7 cells were incubated for 18 h in the absence [Cnt(−)] or presence of 0.7 ug/ml (˜9 nM) WT PCSK9 protein alone [Cnt(+)] or mixed with 50 ug/ml (˜3 uM) of various purified llama sdAbs.

Figure 5 The effect of sdAbs on the gain-of-function PCSK9-D374Y-induced LDLR degradation.

Naive Huh7 cells were incubated for 18 h in the absence [Cnt(−)] or presence of 0.5 ug/ml (˜6 nM) PCSK9-D374Y protein alone [Cnt(+)] or mixed with 50 ug/ml (˜3 uM) of various purified llama sdAbs.

Figure 6 The effect of sdAbs on PCSK9-D374Y gain-of-function mutation-induced LDLR degradation as measured with Dil-LDL uptake assay.

Naive HepG2 cells were incubated for 4 h in the absence [Cnt(−)] or presence of 0.5 μg/mL purified PCSK9-mutant D374Y [Cnt(+)]. The addition of 50 μg/mL of various sdAbs is indicated below.

The effect of sdAbs on the gain-of-function PCSK9-D374Y-induced LDLR degradation.

Naive Huh7 cells were incubated for 18 h in the absence [Cnt(−)] or presence of 0.5 ug/ml (˜6 nM) PCSK9-D374Y protein alone [Cnt(+)] or mixed with increasing concentrations of PKF8 sdAbs.